Background: According to various authors, the prevalence of hyperuricemia in patients with psoriatic arthritis constitutes up to 35% of the total patient population. Thus, seronegative spondylarthritis patients, as it is known, possess a higher incidence of cardiovascular mortality than the population in general, in particular due to life-threatening cardiac arrhythmias. Objectives: To study the effect of hyperuricemia on the development of ventricular extrasystole in patients with psoriatic arthritis and the interrelation of uric acid levels and gradation of ventricular extrasystole. Methods: The study involved patients with psoriatic arthritis, confirmed by CASPAR criteria (2006), n=59. The average age -57.15±12.11 years. All patients underwent the study of myocardial contractility and treadmill test. Inclusion criteria -the presence of psoriatic arthritis for the period of at least one year, uric acid levels over 360 mkmol/L for women and more than 420 mkmol/L for men. The exclusion criteria included the presence of coronary heart disease, myocardial contractility disorders and decreased ejection fraction according to Simpson less than 55%. For all patients was recorded Holter ECG for the period of 24 hours on an outpatient basis. The level of uric acid was measured by means of the standard method of biochemical analyzer.
Background: Dactylitis is a hallmark manifestation of psoriatic arthritis (PsA) and a key feature for PsA diagnosis. Active dactylitis is associated with a higher risk of erosions and can severely impact function. The therapeutic strategies for dactylitis are however largely empirical, with a profound absence of knowledge regarding efficacy, as primary endpoint, and impact on disease progression. The use of biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with dactylitis, refractory to non-steroidal anti-inflammatory drugs (NSAIDs) or local corticosteroids, is recommended by EULAR guidelines, over the use of conventional DMARDs, based in the scarcity of evidence and properly designed studies in this field. Methods: GO-DACT is an investigator initiated ongoing multicentric trial, involving 13 national Rheumatology departments. Patients older than 18 years, with the diagnosis of PsA and active dactylitis (tenderness score≥1), refractory to NSAIDs, for 3 months, were included. Patients were randomized on a 1:1 ratio, to either MTX in combination with golimumab or placebo, for a period of 24 weeks. The primary aim of this trial is to determine differences of efficacy between the two treatment arms, in improving dactylitis (and enthesitis), as assessed by the dactylitis severity score (DSS) at 24 weeks. Key secondary outcomes include: Leeds dactylitis index (LDI), Leeds enthesitis index (LEI), joint counts, psoriasis area and severity index (PASI) and nail psoriasis severity index (NAPSI), health assessment questionnaire (HAQ), Dermatology life quality index (DLQI) and composite indexes for disease activity. The effect of treatment arms, on different tissue compartments, will be analysed by contrast-enhanced magnetic resonance imaging (MRI), with high resolution images for dactylitis, at baseline and 24 weeks.
Results:
The results from GO-DACT are expected to have implications in clinical practice, bringing robust and valid data for the definition of dactylitis treatment stratification and algorithm.GO-DACT will also contribute to understand dactylitis pathogenesis through the assessment of treatment efficacy, namely in distinct tissue compartments as defined by MRI. https://www.clinicaltrials.gov (NCT02065713)
